| 2024/05/02 17:03:53 | |
|---|---|
| Price | |
| 65.345 USD | |
| Difference | -0.25% (-0.17) |
General attributes
| ISIN | US3755581036 |
| Symbol | GILD |
| Exchange | Nasdaq |
| Currency | USD |
| Sector | Chemical / Pharmaceutical / Health |
| Security type | Stock |
| Market cap (m) | 76,226 EUR |
| Benchmark | S&P 500 |
Market data
| Bid (Bid size) | 65.34 USD (100) |
| Ask (Ask size) | 65.35 USD (200) |
| Open | 65.75 USD |
| High | 65.80 USD |
| Low | 64.89 USD |
| Close (prev. day) | 65.51 USD |
| VWAP | 65.250022 USD |
| Volume (pcs) | 1,182,008 |
| Trading volume | 77,141,184.37 |
| Number of trades | 15,447 |
| Last size | 149 |
Futures and Options
| Related Futures | 15 |
| Related Options | - |
PDF Downloads
| Company report: GILEAD SCIENCES INC. |  |
Scale: ABS REL
Instrument
Add Benchmark:
Information about previous performance does not guarantee future performance.Source: FactSet
Recent research
| Date | Headline | Download | |
| 2024/04/26 |
|
Global Equity Ratings |
|
| 2024/04/03 |
|
Global Equity Ratings |
|
| 2024/03/26 |
|
Global Strategy 2Q 2024 |
|
| 2024/03/13 |
|
Global Equity Ratings |
|
| 2024/02/22 |
|
Global Equity Ratings |
|
| 2024/05/02 17:03:53 | |
|---|---|
| Price | |
| 65.345 USD | |
| Difference | -0.25% (-0.17) |
General attributes
| ISIN | US3755581036 |
| Symbol | GILD |
| Exchange | Nasdaq |
| Currency | USD |
| Sector | Chemical / Pharmaceutical / Health |
| Security type | Stock |
| Market cap (m) | 76,226 EUR |
| Benchmark | S&P 500 |
Market data
| Bid (Bid size) | 65.34 USD (100) |
| Ask (Ask size) | 65.35 USD (200) |
| Open | 65.75 USD |
| High | 65.80 USD |
| Low | 64.89 USD |
| Close (prev. day) | 65.51 USD |
| VWAP | 65.250022 USD |
| Volume (pcs) | 1,182,008 |
| Trading volume | 77,141,184.37 |
| Number of trades | 15,447 |
| Last size | 149 |
Performance and Risk
| 6m | 1Y | 3Y | |
| Perf (%) | -16.63% | -18.15% | +15.75% |
| Perf (abs.) | -12.18 | -13.54 | +8.31 |
| Beta | 0.36 | 0.48 | 0.46 |
| Volatility | 25.65 | 22.21 | 22.27 |
Scale: ABS REL
Instrument
Add Benchmark:
Information about previous performance does not guarantee future performance.Source: FactSet
Price data
| Ø price 5 days | Ø volume 5 days (pcs.) | 65.468 USD (10,012,469) |
| Ø price 30 days | Ø volume 30 days (pcs.) | 69.114 USD (7,055,319) |
| Ø price 100 days | Ø volume 100 days (pcs.) | 75.350 USD (7,359,353) |
| Ø price 250 days | Ø volume 250 days (pcs.) | 76.458 USD (6,334,041) |
| YTD High | date | 87.865 USD (2024/01/19) |
| YTD Low | date | 64.630 USD (2024/04/26) |
| 52 Weeks High | date | 87.865 USD (2024/01/19) |
| 52 Weeks Low | date | 64.630 USD (2024/04/26) |
All listings for GILEAD SCIENCES INC.
| Exchange | Date | Time | Price | Trading volume (mio.) | Number of trades |
| Xetra | 2024/05/02 | 17:02 | 61.18 EUR | 0.10 | 40 |
| Vienna Stock Exchange | 2024/05/02 | 09:05 | 61.10 EUR | 0.00 | 1 |
| Tradegate | 2024/05/02 | 17:00 | 61.25 EUR | 0.59 | 68 |
| Stuttgart | 2024/05/02 | 15:32 | 61.24 EUR | 0.03 | 7 |
| SIX Swiss Exchange | 2022/11/02 | 17:36 | 79.50 CHF | 0.00 | 1 |
| SIX Swiss Exchange | 2020/04/17 | 17:35 | 85.00 USD | 0.00 | 1 |
| Nasdaq | 2024/05/02 | 17:03 | 65.345 USD | 77.19 | 15,453 |
| Munich | 2024/05/02 | 08:05 | 60.93 EUR | 0.00 | 1 |
| London Stock Exchange European Trade Reporting | 2024/05/02 | 09:04 | 65.28 USD | 0.00 | 3 |
| Hanover | 2024/05/02 | 08:22 | 60.33 EUR | 0.00 | 1 |
| Hamburg | 2024/05/02 | 16:29 | 61.28 EUR | 0.01 | 3 |
| Frankfurt | 2024/05/02 | 08:31 | 60.28 EUR | 0.00 | 1 |
| Euronext Milan MTF Trading After Hours | 2024/04/05 | 18:23 | 64.51 EUR | 0.00 | 1 |
| Euronext Milan MTF Global Equity Market | 2024/05/02 | 15:57 | 60.67 EUR | 0.02 | 5 |
| Duesseldorf | 2024/05/02 | 16:30 | 61.25 EUR | 0.00 | 4 |
| Berlin | 2024/05/02 | 08:08 | 61.22 EUR | 0.00 | 1 |
Company Logo
Contact Details
| GILEAD SCIENCES INC. |
| - - |
| 333 Lakeside Drive - 94404 Foster City |
| Telefon: +1-650-574-3000 |
| Fax: +1-650-522-5853 |
| E-mail: - |
PDF Downloads
| Company report: GILEAD SCIENCES INC. | |
Company Profile
Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm's primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases. It offers antiviral products under Harvoni, Genvoya, Epclusa, Truvada, Atripla, Descovy, Stribild, Viread, Odefsey, Complera/Eviplera, Sovaldi, and Vosevi brands. The company was founded by Michael L. Riordan on June 22, 1987 and is headquartered in Foster City, CA. |
Members of Management Board
| Jacqueline Barton | Member of Board of Directors |
| Jeffrey Bluestone | Member of Board of Directors |
| Sandra Horning | Member of Board of Directors |
| Ted Love | Member of Board of Directors |
| Anthony Welters | Member of Board of Directors |
| Harish M. Manwani | Member of Board of Directors |
| Javier Rodriguez | Member of Board of Directors |
| Kelly Kramer | Member of Board of Directors |
| Kevin Lofton | Member of Board of Directors |
| Daniel O'Day | Chairman of Managing Board |
| Andrew Dickinson | Member of Executive Committee |
| Deborah H. Telman | Member of Executive Committee |
| Flavius Martin | Member of Executive Committee |
| Johanna Mercier | Member of Executive Committee |
| Jyoti Mehra | Member of Executive Committee |
| MD, PhD Merdad Parsey | Member of Executive Committee |
| Stacey Ma | Member of Executive Committee |